Celgene & the Multiple Sclerosis Association of America Team Up to Launch MS MindShift for Awareness of Multiple Sclerosis & ...
May 21 2019 - 8:00AM
Business Wire
“Brain Bulb” Hot Air Balloon Takes Flight in
NYC Area to Elevate Importance of Brain Preservation
Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis
Association of America (MSAA) today announced the launch of a new
campaign, MS MindShift: A New View of MS, a national initiative
that provides new perspective on multiple sclerosis (MS). The
campaign aims to educate about the critical role the brain plays in
the disease and what people living with MS can do to keep their
brain as healthy as possible, for as long as possible.
To bring this new perspective on MS closer to the community, the
campaign will host engaging, educational events in various cities.
Select events, including the New York City area launch, will
feature the MS MindShift “Brain Bulb” hot air balloon as a way to
literally elevate the importance of having a “brain first”
perspective in MS. Just as keeping a balloon in good condition
keeps it soaring above the ground, shifting focus up toward the
brain today could change how people with MS live with the disease
tomorrow. The initiative launches today in the NYC area, just in
time for World MS Day on May 30, 2019, with additional pop-up
educational events in Philadelphia and Atlanta.
MS is a chronic and often debilitating disease that affects
nearly 1 million people in the U.S. In MS, the immune system
attacks the central nervous system -- which includes the spinal
cord and brain. Localized injury to the brain produces “lesions”
which disrupt the flow of information from the brain to the body
which may lead to symptoms and relapses.
“Brain lesions can cause the affected area to lose proper
function. When this occurs the brain has the amazing ability, known
as neurological reserve, to utilize other areas for rerouting
signals and performing the task the affected area no longer can,”
says Dr. Barry Singer, Director of The MS Center for Innovations in
Care at Missouri Baptist Medical Center, St. Louis, MO. “It’s
crucial for patients to understand the role of the brain in MS and
how lifestyle changes may help maintain neurological reserve
longer.”
“We are excited to partner with Celgene to help elevate the
important topic of brain health that is not often discussed within
the MS community,” says Amanda Montague, Vice President of
Education and Healthcare Relations, MSAA. “The MS MindShift
initiative aligns with our mission to help improve the lives of
people living with MS by providing them with the knowledge and
support needed to help manage their condition.”
All of the MS MindShift events will give the MS community the
opportunity to learn more about the campaign first hand and receive
educational materials. Select cities will feature the Brain Bulb
Balloon and provide a chance to take a “lift up” in the tethered
hot air balloon while learning about a new perspective on MS. To
find out where the MS MindShift events are taking place, visit
MSMindShift.com/events.
“We hope the MS MindShift campaign provides new perspective to
people living with MS,” said Terrie Curran, President, Global
Inflammation and Immunology, Celgene. “Our diverse engagement with
the community through programs like MS MindShift is part of our
continued commitment to providing resources and supporting those
living with this disease.”
People with MS and those who support them can learn more about
the campaign at MSMindShift.com, or join the online community on
Facebook. For more information about the MS MindShift events, visit
MSMindShift.com/events.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey,
is an integrated global biopharmaceutical company engaged primarily
in the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow
Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with the U.S.
Securities and Exchange Commission, including factors related to
the proposed transaction between Bristol-Myers Squibb and Celgene,
such as, but not limited to, the risks that: management’s time and
attention is diverted on transaction related issues; disruption
from the transaction make it more difficult to maintain business,
contractual and operational relationships; legal proceedings are
instituted against Bristol-Myers Squibb, Celgene or the combined
company could delay or prevent the proposed transaction; and
Bristol-Myers Squibb, Celgene or the combined company is unable to
retain key personnel.
Hyperlinks are provided as a convenience and for informational
purposes only. Celgene bears no responsibility for the security or
content of external websites.
All trademarks are the property of their respective owners.
© 2019 Celgene Corporation 05/19 US-CLG-19-0389
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190521005416/en/
Investors:Nina GoworekExecutive Director, Investor
Relations908-673-9711
Media:Catherine CantoneSenior Director, Corporate
Communications908-897-4256
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Oct 2023 to Oct 2024